Neurocrine Biosciences (NBIX) Net Income towards Common Stockholders (QoQ) (2010 - 2026)
Neurocrine Biosciences (NBIX) Net Income towards Common Stockholders (QoQ) (2010 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 43.81 Bn | 42.84 Bn | - |
| 2 | Teva Pharmaceutical Industries | 43.29 Bn | 39.63 Bn | 2.15 Bn |
| 3 | Zoetis | 31.59 Bn | 29.91 Bn | 1.05 Bn |
| 4 | Takeda Pharmaceutical | 28.67 Bn | 22.88 Bn | 5.10 Bn |
| 5 | United Therapeutics | 22.24 Bn | 19.58 Bn | 683.80 Mn |
| 6 | Viatris | 18.79 Bn | 17.91 Bn | 1.46 Bn |
| 7 | Neurocrine Biosciences | 15.71 Bn | 15.32 Bn | 935.80 Mn |
| 8 | Elanco Animal Health | 12.09 Bn | 11.56 Bn | 798.00 Mn |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.95 Bn | - |
| 10 | Alkermes | 8.19 Bn | 7.53 Bn | 397.90 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -27.03% |
| Mar 31, 2026 | 28.76% |
| Dec 31, 2025 | -26.63% |
| Sep 30, 2025 | 94.88% |
| Jun 30, 2025 | 1,260.76% |
| Mar 31, 2025 | -92.34% |
| Dec 31, 2024 | -20.57% |
| Sep 30, 2024 | 99.69% |
| Jun 30, 2024 | 49.77% |
| Mar 31, 2024 | -70.62% |
| Dec 31, 2023 | 77.74% |
| Sep 30, 2023 | -12.98% |
| Jun 30, 2023 | 224.67% |
| Mar 31, 2023 | -186.07% |
| Dec 31, 2022 | 29.93% |
| Sep 30, 2022 | 505.33% |
| Jun 30, 2022 | -221.58% |
| Mar 31, 2022 | 290.41% |
| Dec 31, 2021 | -132.44% |
| Sep 30, 2021 | -46.81% |